Endocrine Abstracts

There are much controversy adjuvant radioiodine treatment (131-I-th) in intermediate or low risk patients with lymph node micrometastases. The first results of ESTIMABL2 trial showed no radioiodine benefit in low risk DTC, however intermediate patients were not included in this study.Aim: Observational study was to evaluate effects of 131-I-th in intermediate/low risk DTC patients.Patients: There were 342 women (85%), the median ag...

Background: Although recombinant human TSH (rhTSH) is widely used to aid radioiodine treatment of differentiated thyroid cancer (DTC), however, there are data on its effectivness in children and adolescents with DTC.The aim of our retrospective study was to evaluate effectiveness and safety of rhTSH aided radioiodine treatment in DTC patients 18 years of age or younger.Material and Methods: Fifty five children/adolescents (median a...

Background: Differentiated thyroid carcinoma (DTC) in children is a rare cancer, occurring in 1/100,000 children/year. In the adults a steady increase in the incidence and change in presentation of DTC has been observed over the past 30 years.Purpose: Evaluation of changes in the clinical presentation of paediatric DTC on the example of children treated in Institute of Oncology in Gliwice between 1970 and 2015.Material and methods:...

Background: Total thyroidectomy and cervical lymph node resection is the standard treatment for MTC, as the cancer often occurs in both thyroid lobes and the incidence of lymph node metastasis reaches 80%, especially in patients with palpable tumor. However, previous analyses have included both hereditary and sporadic MTCs. In the ultrasound era, patients are referred for surgery earlier, often with not palpable MTCs, and the result of the germline RET oncogene mutation analys...